Certara, the global model-informed drug development and decision support leader, recently announced the launch of Phoenix 8.2, the industry gold standard in pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation software for drug development
Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, and Atomwise, Inc. (“Atomwise”), the leader in artificial intelligence (AI) for drug discovery, have announced a collaboration to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas
Atomwise Inc. (“Atomwise”), the leader in artificial intelligence (AI) for drug discovery, recently announced a collaboration with Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas
Puma Biotechnology, Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed therapy (third-line disease)
Tubulis, a company developing uniquely matched protein drug conjugates, and Glycotope, a clinical-stage immuno-oncology company recently announced that they have signed a research and feasibility agreement, providing Glycotope access to Tubulis’ proprietary antibody drug conjugate (ADC) technologies
SEngine Precision Medicine and Atomwise, Inc. recently announced a joint venture to accelerate novel oncology drug discovery utilizing the unique platform technologies each company has validated through years of development
Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, recently announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH)
Aptorum Group Limited (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the development of two preclinical drug candidates which target obesity and neuroblastoma, respectively
Charles River Laboratories International, Inc. is proud to host the 3rd Annual World Congress: Delivering Therapies to the Clinic Faster on September 23-24, 2019 in Cambridge, Mass
Schrödinger recently announced the expansion of its multi-year, multi-target drug discovery collaboration with Takeda, as well as Schrödinger’s achievement of the first significant preclinical milestone for the collaboration’s most advanced program
|
|
|
|
|
|
|
|
|